Boston Scientific Corporation (BSX)
BSX Stock Price Chart
Key Info
| Market Cap | 49.27B |
| Revenue (ttm) | 10.11B |
| Net Income (ttm) | 3.69B |
| Shares Out | 1.43B |
| EPS (ttm) | 2.61 |
| PE Ratio | 13.21 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $34.41 |
| Previous Close | $33.81 |
| Change ($) | 0.60 |
| Change (%) | 1.77% |
| Day's Open | 33.80 |
| Day's Range | 33.57 - 34.42 |
| Day's Volume | 26,382,462 |
| 52-Week Range | 25.83 - 45.71 |
BSX Stock News
Biotech stocks are vulnerable to headlines, but these three have too much potential to ignore. Own them for a swing trade into 2021.
BTG's core Interventional Medicines business now is expected to exceed Boston Scientific's (BSX) original goal of $175 million in synergies.
Boston Scientific Corp. said Tuesday it is selling its BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, both affiliates of specialty pharma group SERB, ...
MARLBOROUGH, Mass., Dec. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L....
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). ...
Here is an interesting fact. While most stocks have been climbing, Boston Scientific's stock is doing something different.
MARLBOROUGH, Mass., Nov. 23, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahon...
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating potential claims against Boston Scientific Corporation (NYSE: BSX) ("BSX" or the ...
Despite a 47% rise since the March lows, at the current price of around $38 per share we believe Boston Scientific stock, has more room for growth in the near term. BSX stock has rallied from ...
Boston Scientific Corp. said Tuesday it has launched a voluntary recall of unused stock of its LOTUS Edge Aortic Valve System due to "complexities" relating to the product delivery system. "Th...
Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
MARLBOROUGH, Mass., Nov. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, ...
MARLBOROUGH, Mass., Nov. 2, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, de...
MARLBOROUGH, Mass., Oct. 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX...
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q3 2020 Results - Earnings Call Transcript
Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.
Boston Scientific (BSX) delivered earnings and revenue surprises of 48.00% and 5.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...
MARLBOROUGH, Mass., Oct. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1....
Boston Scientific Corp. posted a better-than-expected third-quarter adjusted profit and sales that topped estimates. The Marlborough, Mass.
In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.
Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
While technology has been the engine that has driven stock market performance for some time now, increasingly we are seeing a seismic shift to health care among many portfolio managers, and wi...
MARLBOROUGH, Mass., Oct. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) o...
MARLBOROUGH, Mass., Sept. 30, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems....
MARLBOROUGH, Mass., Sept. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Eu...
Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.
We believe Boston Scientific stock could see an upside of over 10% in the near term. BSX stock trades at $39 currently and it has lost 15% of its value so far this year.
MARLBOROUGH, Mass., Sept. 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse...
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
Final Trades: Seattle Genetics, Booking Holdings, Boston Scientific & more
The "Halftime Report" traders give their top picks to watch for the second half.
MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Ve...
Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.
MARLBOROUGH, Mass., Sept. 3, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced that the U.S.
Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
MARLBOROUGH, Mass., Aug. 26, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences.
Though Boston Scientific (NYSE: BSX) has seen its stock rise by over 50% since the March 23 lows, it is still down by 13% year-to-date. The stock now trades at over 39x projected 2020 earnings...
Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.
LONDON, Aug. 17, 2020 /PRNewswire/ -- BTG Specialty Pharmaceuticals, a division of Boston Scientific (NYSE:BSX), today announced the European Medicines Agency (EMA) has accepted for review a M...
Boston Scientific: This Healthcare Technology Company Is Poised To Thrive
New products mean solid revenue may be ahead for these companies.
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q2 2020 Results - Earnings Call Transcript
Final Trades: Akamai, General Motors, Boston Scientific & more
The "Halftime Report" traders give their top picks to watch for the second half.
This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.
Boston Scientific (BSX) delivered earnings and revenue surprises of 300.00% and 22.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific earnings were positive on adjusted basis. Analysts expected the medical device giant to report a loss.
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r... [Read more...]
| Industry Medical Devices | IPO Date May 18, 1992 |
| CEO Michael Mahoney | Employees 36,000 |
| Stock Exchange NYSE | Ticker Symbol BSX |
Financial Performance
In 2019, BSX's revenue was $10.74 billion, an increase of 9.28% compared to the previous year's $9.82 billion. Earnings were $4.70 billion, an increase of 181.27%.
Analyst Forecasts
According to 27 analysts, the average rating for BSX stock is "Buy." The 12-month stock price forecast is 43.46, which is an increase of 26.30% from the latest price.